Roche's Columvi Meets Main Goal in Lymphoma Phase 3 Trial
By Adria Calatayud
Roche Holding said its Columvi drug helped lymphoma patients who had received at least one prior treatment live longer in a phase 3 clinical trial, meeting the primary goal of the study.
The Swiss pharmaceutical giant said Monday that Columvi, in combination with chemotherapy, showed a statistically significant improvement in overall survival for people with diffuse large B-cell lymphoma--a form of blood cancer--who had received at least one prior line of therapy and weren't candidates for transplant of their own stem cells.
Roche said safety of the drug combination appeared consistent with the known safety profiles of the individual medicines.
Data from the trial will be submitted to health authorities, the company said. Roche intends to publish more details at an upcoming medical meeting, it said.
Columvi already received approval by the U.S. Food and Drug Administration and conditional authorization from the European Commission to treat people with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of therapy, Roche said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
April 15, 2024 01:39 ET (05:39 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now